Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Akoya Biosciences Q2 2024 GAAP EPS $(0.27), Inline, Sales $23.164M Miss $23.552M Estimate

Author: Benzinga Newsdesk | August 05, 2024 04:02pm
Akoya Biosciences (NASDAQ:AKYA) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. The company reported quarterly sales of $23.164 million which missed the analyst consensus estimate of $23.552 million by 1.65 percent. This is a 1.52 percent decrease over sales of $23.521 million the same period last year.

Posted In: AKYA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist